Comparing Cytokinetics’ aficamten with BMS’s Camzyos

Cytokinetics’ recent Phase III data suggest aficamten might have a slight edge over Camzyos, the only drug on the market that addresses the underlying cause of obstructive hypertrophic cardiomyopathy.

Both products are small molecule cardiac myosin inhibitors administered once daily. FDA approved Camzyos mavacamten in April 2022, less than two years after Bristol Myers Squibb Co. (NYSE:BMY) gained the drug via its $13.1 billion acquisition of MyoKardia Inc. ...